Passive immunotherapy has been used since the late 19th century, and in 1901, the first Nobel Prize in Physiology or Medicine was awarded for serum therapy for patients with diphtheria. During the 1918 pandemic, serum from convalescent patients was used to treat influenza, with some apparent success.1 Today, the use of immunoglobulins has been established for the prophylaxis and treatment of a variety of infections, including those with respiratory syncytial virus, cytomegalovirus, and hepatitis B or hepatitis A virus. More recently, passive immunotherapy has been evaluated for severe acute respiratory syndrome (SARS), Middle East respiratory syndrome, and Ebola virus disease.https://www.nejm.org/doi/full/10.1056/NEJMe2035678?rss=mostViewed
The views and opinions expressed in this feed are those of the authors and do not necessarily reflect the official policy or position of Elizabeth Pharmacy. Elizabeth Pharmacy does not warrant the accuracy, timeliness or completeness of the information contained on this feed. If you have a particular complaint about something you’ve found on this web site, feel free to contact us.